- Home
- CRVS vs KOP Comparison
CRVS vs KOP Comparison
Compare CRVS & KOP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRVS
- KOP
- Stock Information
- Founded
- CRVS 2014
- KOP 1988
- Country
- CRVS United States
- KOP United States
- Employees
- CRVS N/A
- KOP N/A
- Industry
- CRVS Biotechnology: Pharmaceutical Preparations
- KOP Forest Products
- Sector
- CRVS Health Care
- KOP Basic Materials
- Exchange
- CRVS Nasdaq
- KOP Nasdaq
- Market Cap
- CRVS 516.0M
- KOP 614.6M
- IPO Year
- CRVS 2016
- KOP 2006
- Fundamental
- Price
- CRVS $5.22
- KOP $32.37
- Analyst Decision
- CRVS Strong Buy
- KOP Buy
- Analyst Count
- CRVS 5
- KOP 1
- Target Price
- CRVS $12.38
- KOP $64.00
- AVG Volume (30 Days)
- CRVS 1.6M
- KOP 165.0K
- Earning Date
- CRVS 11-12-2024
- KOP 02-26-2025
- Dividend Yield
- CRVS N/A
- KOP 0.87%
- EPS Growth
- CRVS N/A
- KOP N/A
- EPS
- CRVS N/A
- KOP 3.52
- Revenue
- CRVS N/A
- KOP $2,128,300,000.00
- Revenue This Year
- CRVS N/A
- KOP N/A
- Revenue Next Year
- CRVS N/A
- KOP $1.54
- P/E Ratio
- CRVS N/A
- KOP $9.03
- Revenue Growth
- CRVS N/A
- KOP 0.22
- 52 Week Low
- CRVS $1.30
- KOP $29.26
- 52 Week High
- CRVS $10.00
- KOP $58.23
- Technical
- Relative Strength Index (RSI)
- CRVS 41.23
- KOP 50.17
- Support Level
- CRVS $4.60
- KOP $31.33
- Resistance Level
- CRVS $6.47
- KOP $32.46
- Average True Range (ATR)
- CRVS 0.39
- KOP 0.88
- MACD
- CRVS 0.06
- KOP 0.31
- Stochastic Oscillator
- CRVS 33.16
- KOP 83.83
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the critical cellular elements of the immune system. It focuses on the development of immune modulator product candidates to treat COVID-19, T-cell lymphomas, other cancers, and autoimmune diseases. The company's primary product candidate is Soquelitinib (CPI-818), an oral, small-molecule drug that selectively inhibits ITK (interleukin-2-inducible T cell kinase). The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).
About KOP Koppers Holdings Inc.
Koppers Holdings Inc through its subsidiaries, manufactures and sells wood products, wood treatment chemicals, and carbon compounds used in markets such as railroad, aluminum and steel, agriculture, utilities, and residential lumber. The company is organized into three business segments: railroad and utility products and services, performance chemicals, and carbon materials and chemicals. Its product portfolio includes treated and untreated wood products like crossties used in railroads, wood preservation chemicals, and carbon compounds such as creosote used in the treatment of wood crossties, among others. The majority of its revenue comes from the company's railroad and utility products and services segment, and more than half of the company's revenue is earned in the United States.